CRP and metastatic prostate carcinoma: In evaluating a cohort of 62 patients with metastatic prostate cancer on androgen deprivation therapy, CRP and PSA were evaluated simultaneously; higher levels of both CRP and PSA were independent predictors of poorer cancer-specific survival.